Trial Profile
Observational Cohort Study to Characterize the Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 14 Mar 2022 Planned primary completion date changed from 30 Dec 2022 to 1 Jun 2022.
- 14 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 29 Jun 2017 New trial record